| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18822679 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 116 journal articles in the PubMed database | Email to a friend | | |
| Di Lauro V, Murrone A, Bidoli E, et al.
Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience. [Journal Article]
Tumori 2008 Jul-Aug; 94(4):464-8.
Abstract | Full Citation | Find Related Articles | | Sawaki M, Ito Y, Tada K, et al.
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. [Journal Article]
Tumori 2004 Jan-Feb; 90(1):40-3.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Burstein HJ, Harris LN, Marcom PK, et al.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
J Clin Oncol 2003 Aug 1; 21(15):2889-95.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Gori S, Colozza M, Mosconi AM, et al.
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Br J Cancer 2004 Jan 12; 90(1):36-40.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | De Maio E, Pacilio C, Gravina A, et al.
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. [JOURNAL ARTICLE]
BMC Cancer 2007 Mar 20; 7(1):50.
Abstract | Full Citation | | Burstein HJ, Kuter I, Campos SM, et al.
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2001 May 15; 19(10):2722-30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Pegram MD, Pienkowski T, Northfelt DW, et al.
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
J Natl Cancer Inst 2004 May 19; 96(10):759-69.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Burstein HJ, Keshaviah A, Baron AD, et al.
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. [JOURNAL ARTICLE]
Cancer 2007 Jul 5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Stemmler HJ, Kahlert S, Brudler O, et al.
High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. [Clinical Trial, Phase II, Journal Article, Multicenter Study]
Clin Oncol (R Coll Radiol) 2005 Dec; 17(8):630-5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
